Roche (VTX:ROG) has been assigned a CHF 195 price target by equities researchers at Societe Generale in a note issued to investors on Wednesday. The brokerage presently has a “sell” rating on the healthcare company’s stock. Societe Generale’s price objective would suggest a potential downside of 14.57% from the stock’s current price.
ROG has been the subject of several other reports. Liberum Capital set a CHF 279 price objective on Roche and gave the stock a “buy” rating in a research report on Wednesday, November 22nd. Jefferies Group set a CHF 300 price objective on Roche and gave the stock a “buy” rating in a research report on Friday, January 5th. JPMorgan Chase & Co. set a CHF 300 price objective on Roche and gave the stock a “buy” rating in a research report on Thursday, January 4th. Barclays set a CHF 305 price objective on Roche and gave the stock a “buy” rating in a research report on Thursday, December 21st. Finally, Goldman Sachs Group set a CHF 325 target price on Roche and gave the company a “buy” rating in a research report on Wednesday, December 13th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of CHF 255.05.
Shares of Roche (ROG) traded up CHF 0.05 during mid-day trading on Wednesday, hitting CHF 228.25. The company had a trading volume of 2,170,000 shares, compared to its average volume of 2,130,000. Roche has a twelve month low of CHF 214.30 and a twelve month high of CHF 273. The company has a market cap of $197,010.00 and a P/E ratio of 22.73.
TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/03/14/roche-rog-given-a-chf-195-price-target-by-societe-generale-analysts.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.